[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100504261":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":26,"centralContacts":26,"locations":34,"responsibleParty":48,"collaborators":26,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":26,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":26,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":26,"overallStatus":70,"whyStopped":26,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Sanofi","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"SAR441344","EXPERIMENTAL","Single or multiple Ascending dose of SAR441344 Dose 1 administered intravenously and\u002For subcutaneously",[13,14],"Drug: SAR441344","Biological: Keyhole limpet hemocyanin",{"label":16,"type":17,"description":18,"interventionNames":19},"placebo","PLACEBO_COMPARATOR","matching placebo",[20,14],"Drug: placebo",[22,27,29],{"type":23,"name":9,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Solution for intravenous\u002Fsubcutaneous injection",[9],null,{"type":23,"name":16,"description":24,"armGroupLabels":28,"otherNames":26},[16],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":26},"BIOLOGICAL","Keyhole limpet hemocyanin","Subcutaneous Lyophilized powder for reconstitution",[9,16],[35],{"facility":36,"status":26,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":26},"PPD-Site Number:8400001","Austin","Texas","78744","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-97.74306,30.26715,{"lat":46,"lon":45},{"type":49,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100504261","phase-1-study-of-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-intravenous-and-subcutaneous-single-and-repeated-doses-of-sar441344-in-healthy-adult-subjects-100504261",false,"NCT05845996","Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects","A Randomized, Double-blind, Parallel Design, Placebo-controlled Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Doses of SAR441344 in Healthy Adult Subjects","Inclusion criteria\n\n\\- Having given written informed consent prior to undertaking any study-related procedure.\n\nExclusion criteria\n\n\\- Any subject who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",true,"ALL","18 Years","45 Years",{"count":62,"type":63},56,"ACTUAL","INTERVENTIONAL",[66],"PHASE1","Primary Objective is the tolerability and safety of ascending single and repeated intravenous infusion (IV) and\u002For subcutaneous (SC) administration of SAR441344",[69],"Healthy Volunteers","COMPLETED","2025-09-10",{"date":73,"type":63},"2025-09-16",{"date":75,"type":63},"2018-11-08",{"date":77,"type":63},"2020-04-10",{"name":5,"class":6},1]